Skip to content
peptide

PE-22-28

anecdotalResearch Use OnlyIntranasalInjection

Rapid-acting antidepressant peptide. Inhibits TREK-1 potassium channels, boosting neuronal excitability and triggering fast BDNF upregulation. Mouse studies show antidepressant effects within days.


Key facts
Classification
Peptide — Fast-acting antidepressant and cognitive enhancer. Blocks TREK-1 channels.
Primary benefits
Brain & Cognition (8/10) · Mood & Anxiety (7/10)
Administration
Intranasal, Injection
Doses studied
200-500 mcg as a nasal spray or subq daily. Cycle 4 weeks on, then take a break.
Evidence strength
Anecdotal — 21 peer-reviewed studies
Stacks well with
Semax, Selank
Legal status
Research Use Only · not prescribable in US
Quick stats
Type
Peptide
Administration
Intranasal, Injection
Studies referenced
21
Stacks with
2 peptides
Regulatory
Research Use Only
Goal coverage · PE-22-28
🧠 Brain & Cognition8/10
😌 Mood & Anxiety7/10
FIG.1  Modeled goal coverage from reviewed studies. Score out of 10.
From our network:Cornerstone Peptide